Skip to Main Content

How do you describe a one-in-a-million risk? What’s heparin-induced thrombocytopenia? And why’s it so hard to find drugs for Covid-19?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, Science Magazine reporter Kai Kupferschmidt joins us to discuss the U.S. decision to press pause on the Johnson & Johnson vaccine and what researchers have learned about rare cases of dangerous clotting. Then, biotech analyst Josh Schimmer joins us to talk about why the drug industry has had such a hard time coming up with treatments for Covid-19 and offer some tips that might help in the next pandemic.


For more on what we cover, here’s the latest on J&J; here’s where you can find Kupferschmidt’s work; here’s more on the quest for Covid-19 drugs; here’s where you can subscribe to the First Opinion Podcast; and here’s our complete coverage of the coronavirus pandemic.

Be sure to sign up on Apple PodcastsStitcherGoogle Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].


Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].

  • The concern of the blood clots, maybe is related to medicines the people are taking that let them fragile, like the anticonceptive pils ? And the vaccine has nothing to do with it, some people are more proclive to blood cloths, by age and behavior.

Comments are closed.